Market Overview

Collins Stewart Maintains Neutral, $2 PT on Savient Pharmaceuticals


Collins Stewart reiterates its Neutral rating and $2 target price on Savient Pharmaceuticals (NASDAQ: SVNT) as it still waits for an inflection on the company's sales base.

Collins Stewart says, "While patient referrals from the expanded physician base could lead to incremental uptake, we continue to believe significant education is also likely required to meaningfully accelerate the launch trajectory in the near-term. In addition, given management expectations of steady growth outlook vs. prior expectations of a 2Q12 inflection, we are revising our FY12 and FY13 Krystexxa estimates to $25.8M (from $39.4M) and $71.7M (from $83.1M), respectively."

SVNT closed at $2.10 yesterday.


Related Articles (SVNT)

View Comments and Join the Discussion!

Posted-In: Collins StewartAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

Latest Ratings

BPMKM PartnersInitiates Coverage On31.0
BLIStifelInitiates Coverage On105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at